Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224187 | 0.93 | TAAR1 (0.50) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL28709923 | 0.87 | MAOB (0.40) | TAAR1MAOBPTGS1PTGS2HTR2A | |
| SCHEMBL6614163 | 0.85 | MAOB (0.52) | TAAR1MAOBSIGMAR1HTR1ADRD2 | |
| SCHEMBL990098 | 0.84 | TAAR1 (0.56) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL2320532 | 0.84 | TAAR1 (0.62) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL10574057 | 0.84 | TAAR1 (0.62) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL11287580 | 0.83 | TAAR1 (0.42) | TAAR1MAOBIDO1CYP19A1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL13518531 | 0.82 | TAAR1 (0.54) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL10571903 | 0.81 | TAAR1 (0.59) | TAAR1MAOBIDO1LOXL2AOC3 | |
| SCHEMBL9190069 | 0.79 | CA1 (0.39) | TAAR1MAOBPTGS1PTGS2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105390-A | Method for treating addiction | 细胞内治疗公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-2406226-B1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-20140303333-A1 | IRON BISPHENOLATE COMPLEXES AND METHODS OF USE AND SYNTHESIS THEREOF | UNIV PRINCE EDWARD ISLAND (CA) | 2014-10-09 | — | — | US | disclosed |
| US-20140303333-A1 | IRON BISPHENOLATE COMPLEXES AND METHODS OF USE AND SYNTHESIS THEREOF | UNIV PRINCE EDWARD ISLAND (CA) | 2014-10-09 | — | — | US | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| CN-102369188-A | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH | 2012-03-07 | — | — | CN | disclosed |
| EP-2406226-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-5281601-A | Imide substituted indoline derivatives | PFIZER INC. (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0572952-A1 | 4-Benzylpiperidine derivatives, a process for preparing them and pharmaceutical compositions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1993-12-08 | — | — | EP | disclosed |
| WO-1991014679-A1 | HETEROCYCLIC N-SUBSTITUTED DERIVATIVES, THEIR PREPARATION AND THEPHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1991-10-03 | — | — | WO | disclosed |
| WO-1991009015-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| US-4618683-A | Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives | ABBOTT LABORATORIES (US) | 1986-10-21 | — | — | US | disclosed |
| EP-0046590-B1 | PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-05-22 | — | — | EP | disclosed |
| US-4337267-A | HYPOKETONEMIC, HYPOGLYCEMIC, ANTIDIABETIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-06-29 | — | — | US | disclosed |
| WO-1982000643-A1 | SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF | BYK GULDEN LOMBERG CHEM FAB (DE) | 1982-03-04 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
| US-4051190-A | MANUFACTURE OF 3-ARYLPROPYL CHLORIDE | ABBOTT LABORATORIES (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | TAAR1 1486/4885MAOB 263/4885IDO1 1097/4885 |
| US-20140303333-A1 | IRON BISPHENOLATE COMPLEXES AND METHODS OF USE AND SYNTHESIS THEREOF | TFRC, PCBP1, FECH | TAAR1 696/4885MAOB 210/4885IDO1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.